In the grey zone between epilepsy and schizophrenia: alterations in group II metabotropic glutamate receptors

[1]  Xu-Feng Huang,et al.  Metabotropic glutamate receptor mGluR2/3 and mGluR5 binding in the anterior cingulate cortex in psychotic and nonpsychotic depression, bipolar disorder and schizophrenia: implications for novel mGluR-based therapeutics. , 2014, Journal of psychiatry & neuroscience : JPN.

[2]  J. González-Maeso,et al.  Evaluation of 5-HT2A and mGlu2/3 receptors in postmortem prefrontal cortex of subjects with major depressive disorder: Effect of antidepressant treatment , 2014, Neuropharmacology.

[3]  Mark A. Smith,et al.  AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study , 2014, Schizophrenia Research.

[4]  B. Lennox,et al.  Antibodies to the N-Methyl-D-Aspartate Receptor and Other Synaptic Proteins in Psychosis , 2014, Biological Psychiatry.

[5]  S. Dedeurwaerdere,et al.  Hypolocomotive behaviour associated with increased microglia in a prenatal immune activation model with relevance to schizophrenia , 2014, Behavioural Brain Research.

[6]  A. Megens,et al.  Pharmacological Characterization of JNJ-40068782, a New Potent, Selective, and Systemically Active Positive Allosteric Modulator of the mGlu2 Receptor and Its Radioligand [3H]JNJ-40068782 , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[7]  Maria Thom,et al.  International consensus classification of hippocampal sclerosis in temporal lobe epilepsy: A Task Force report from the ILAE Commission on Diagnostic Methods , 2013, Epilepsia.

[8]  G. Marek,et al.  CNS distribution of metabotropic glutamate 2 and 3 receptors: Transgenic mice and [3H]LY459477 autoradiography , 2013, Neuropharmacology.

[9]  Gary F. Egan,et al.  Manganese-enhanced MRI reflects seizure outcome in a model for mesial temporal lobe epilepsy , 2013, NeuroImage.

[10]  S. Russo,et al.  Prenatal Stress Induces Schizophrenia-Like Alterations of Serotonin 2A and Metabotropic Glutamate 2 Receptors in the Adult Offspring: Role of Maternal Immune System , 2013, The Journal of Neuroscience.

[11]  J. Hallak,et al.  Psychiatric comorbidities in temporal lobe epilepsy: possible relationships between psychotic disorders and involvement of limbic circuits. , 2012, Revista brasileira de psiquiatria.

[12]  Stefanie Dedeurwaerdere,et al.  PET imaging of brain inflammation during early epileptogenesis in a rat model of temporal lobe epilepsy , 2012, EJNMMI Research.

[13]  P. Conn,et al.  Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling. , 2012, Discovery medicine.

[14]  M. Inostroza,et al.  Systemic Injection of Kainic Acid Differently Affects LTP Magnitude Depending on its Epileptogenic Efficiency , 2012, PloS one.

[15]  P. Kaplan,et al.  Electroencephalographic criteria for nonconvulsive status epilepticus: Synopsis and comprehensive survey , 2012, Epilepsia.

[16]  Scott J. Russo,et al.  HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity , 2012, Nature Neuroscience.

[17]  M. Goldacre,et al.  Coexistence of schizophrenia and epilepsy: Record‐linkage studies , 2012, Epilepsia.

[18]  D. McKinzie,et al.  Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia , 2012, Neuropharmacology.

[19]  R. Köhling,et al.  Upregulation of presynaptic mGluR2, but not mGluR3 in the epileptic medial perforant path , 2012, Neuropharmacology.

[20]  Alan S. Brown.  Exposure to Prenatal Infection and Risk of Schizophrenia , 2011, Front. Psychiatry.

[21]  R. Coveñas,et al.  Classical neurotransmitters and neuropeptides involved in generalized epilepsy: a focus on antiepileptic drugs. , 2011, Current medicinal chemistry.

[22]  F. Sung,et al.  Bidirectional relation between schizophrenia and epilepsy: A population‐based retrospective cohort study , 2011, Epilepsia.

[23]  B. Kinon,et al.  A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia , 2011, Journal of clinical psychopharmacology.

[24]  E. Frank,et al.  Density of metabotropic glutamate receptors 2 and 3 (mGluR2/3) in the dorsolateral prefrontal cortex does not differ with schizophrenia diagnosis but decreases with age , 2011, Schizophrenia Research.

[25]  X. Langlois,et al.  Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2/3 receptor agonist , 2011, Psychopharmacology.

[26]  Terrell Holloway,et al.  Maternal Influenza Viral Infection Causes Schizophrenia-Like Alterations of 5-HT2A and mGlu2 Receptors in the Adult Offspring , 2011, The Journal of Neuroscience.

[27]  G. Barker,et al.  Neuroanatomical correlates of psychosis in temporal lobe epilepsy: voxel-based morphometry study. , 2010, The British journal of psychiatry : the journal of mental science.

[28]  Marek Kubicki,et al.  Structural neuroimaging in schizophrenia from methods to insights to treatments , 2010, Dialogues in clinical neuroscience.

[29]  S. Chaki.  Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia. , 2010, European journal of pharmacology.

[30]  Kang Sim,et al.  Genetic association studies of glutamate, GABA and related genes in schizophrenia and bipolar disorder: A decade of advance , 2010, Neuroscience & Biobehavioral Reviews.

[31]  K. Perry,et al.  Activation of metabotropic glutamate (mGlu)2 receptors suppresses histamine release in limbic brain regions following acute ketamine challenge , 2010, Neuropharmacology.

[32]  P. Conn,et al.  Metabotropic glutamate receptors: physiology, pharmacology, and disease. , 2010, Annual review of pharmacology and toxicology.

[33]  J. Wierońska,et al.  Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs , 2009, Neurochemistry International.

[34]  S. Sealfon,et al.  Group II metabotropic glutamate receptors and schizophrenia , 2009, Cellular and Molecular Life Sciences.

[35]  C. Tamminga,et al.  Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action? , 2009, The American journal of psychiatry.

[36]  J. Feldon,et al.  In-vivo rodent models for the experimental investigation of prenatal immune activation effects in neurodevelopmental brain disorders , 2009, Neuroscience & Biobehavioral Reviews.

[37]  A. Sawa,et al.  Schizophrenia and epilepsy: Is there a shared susceptibility? , 2009, Neuroscience Research.

[38]  E. Garrido-Sanabria,et al.  Impaired expression and function of group II metabotropic glutamate receptors in pilocarpine-treated chronically epileptic rats , 2008, Brain Research.

[39]  E. Garrido-Sanabria,et al.  Differential changes in mGlu2 and mGlu3 gene expression following pilocarpine-induced status epilepticus: A comparative real-time PCR analysis , 2008, Brain Research.

[40]  Abraham Weizman,et al.  The possible involvement of metabotropic glutamate receptors in schizophrenia , 2008, European Neuropsychopharmacology.

[41]  Graeme Milligan,et al.  Identification of a serotonin/glutamate receptor complex implicated in psychosis , 2008, Nature.

[42]  D. Lorrain,et al.  Distribution of metabotropic glutamate 2 and 3 receptors in the rat forebrain: Implication in emotional responses and central disinhibition , 2008, Brain Research.

[43]  J A Veltman,et al.  CNTNAP2 gene dosage variation is associated with schizophrenia and epilepsy , 2008, Molecular Psychiatry.

[44]  J. Kleinman,et al.  Metabotropic Glutamate Receptor 2 and 3 Gene Expression in The Human Prefrontal Cortex and Mesencephalon in Schizophrenia , 2008, The International journal of neuroscience.

[45]  O. Devinsky,et al.  Psychosis in epilepsy patients , 2007, Epilepsia.

[46]  L. Crepaldi,et al.  Altered Dimerization of Metabotropic Glutamate Receptor 3 in Schizophrenia , 2007, Biological Psychiatry.

[47]  S. Mosolov,et al.  Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial , 2007, Nature Medicine.

[48]  G. Mudó,et al.  Cellular localization of mGluR3 and mGluR5 mRNAs in normal and injured rat brain , 2007, Brain Research.

[49]  S. Platt,et al.  The role of glutamate in central nervous system health and disease--a review. , 2007, Veterinary journal.

[50]  H. Adesnik,et al.  Epilepsy-Related Ligand/Receptor Complex LGI1 and ADAM22 Regulate Synaptic Transmission , 2006, Science.

[51]  D. Godwin,et al.  Metabotropic glutamate receptors as a strategic target for the treatment of epilepsy , 2006, Epilepsy Research.

[52]  E. Sanabria,et al.  Abnormal mGluR2/3 expression in the perforant path termination zones and mossy fibers of chronically epileptic rats , 2006, Brain Research.

[53]  K. Davis,et al.  Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia , 2005, Synapse.

[54]  P. Mortensen,et al.  Risk for schizophrenia and schizophrenia-like psychosis among patients with epilepsy: population based cohort study , 2005, BMJ : British Medical Journal.

[55]  C. Swanson,et al.  Metabotropic glutamate receptors as novel targets for anxiety and stress disorders , 2005, Nature Reviews Drug Discovery.

[56]  G. He,et al.  A case-control study of the relationship between the metabotropic glutamate receptor 3 gene and schizophrenia in the Chinese population , 2005, Schizophrenia Research.

[57]  R. Gibbs,et al.  Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[58]  J. Burgunder,et al.  Metabotropic glutamate receptor 2/3 in the hippocampus of patients with mesial temporal lobe epilepsy, and of rats and mice after pilocarpine-induced status epilepticus , 2004, Epilepsy Research.

[59]  Bita Moghaddam,et al.  Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia , 2004, Psychopharmacology.

[60]  Ravi S. Menon,et al.  Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. , 2003, The American journal of psychiatry.

[61]  B. Meldrum,et al.  Glutamate metabotropic receptors as targets for drug therapy in epilepsy. , 2003, European journal of pharmacology.

[62]  Y. Fukumaki,et al.  Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia , 2003, Psychiatric genetics.

[63]  B. Platt,et al.  Glutamate receptor function in learning and memory , 2003, Behavioural Brain Research.

[64]  Stephan Heckers,et al.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. , 2003, Pharmacology & therapeutics.

[65]  Gregory L. Holmes,et al.  Seizure-induced neuronal injury: Animal data , 2002, Neurology.

[66]  Ravi S. Menon,et al.  Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. , 2002, The American journal of psychiatry.

[67]  M. Corcos,et al.  [Epidemiology and natural history of schizophrenia]. , 2002, La Revue du praticien.

[68]  Y. Fukumaki,et al.  Structure and polymorphisms of the human metabotropic glutamate receptor type 2 gene (GRM2): analysis of association with schizophrenia , 2001, Molecular Psychiatry.

[69]  F R Tang,et al.  Expression of the group II and III metabotropic glutamate receptors in the hippocampus of patients with mesial temporal lobe epilepsy , 2001, Journal of neurocytology.

[70]  D. Schoepp,et al.  Regulation of Neurotransmitter Release by Metabotropic Glutamate Receptors , 2000, Journal of neurochemistry.

[71]  F. D. da Silva,et al.  Upregulation of metabotropic glutamate receptor subtype mGluR3 and mGluR5 in reactive astrocytes in a rat model of mesial temporal lobe epilepsy , 2000, The European journal of neuroscience.

[72]  B. Meldrum,et al.  Glutamate as a neurotransmitter in the brain: review of physiology and pathology. , 2000, The Journal of nutrition.

[73]  K. Davis,et al.  Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus , 2000, Biological Psychiatry.

[74]  R. Roth,et al.  The Neuropsychopharmacology of Phencyclidine: From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia , 1999, Neuropsychopharmacology.

[75]  R. Mailman,et al.  Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation , 1998, Brain Research.

[76]  D. Jane,et al.  Anticonvulsant and glutamate release-inhibiting properties of the highly potent metabotropic glutamate receptor agonist (2S,2′R,3′R)-2-(2′,3′-dicarboxycyclopropyl)glycine (DCG-IV) , 1998, Brain Research.

[77]  P. Sachdev.  Psychosis and epilepsy: The status of the association , 2000 .

[78]  N. Mizuno,et al.  Distribution of a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat and mouse: an immunohistochemical study with a monoclonal antibody , 1998, Neuroscience Research.

[79]  M. Bennett,et al.  Status Epilepticus-Induced Alterations in Metabotropic Glutamate Receptor Expression in Young and Adult Rats , 1997, The Journal of Neuroscience.

[80]  Ayae Kinoshita,et al.  Differential Presynaptic Localization of Metabotropic Glutamate Receptor Subtypes in the Rat Hippocampus , 1997, The Journal of Neuroscience.

[81]  H. Shinozaki,et al.  Anticonvulsive and neuroprotective actions of a potent agonist (DCG-IV) for Group II metabotropic glutamate receptors against intraventricular kainate in the rat , 1997, Neuroscience.

[82]  M. During,et al.  Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain , 1993, The Lancet.

[83]  S. Nakanishi,et al.  Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat , 1993, Neuroscience.

[84]  T. Crow,et al.  A ‘mock-up’ of schizophrenia: Temporal lobe epilepsy and schizophrenia-like psychosis , 1990, Schizophrenia Research.

[85]  P. Flor-Henry,et al.  Psychosis and Temporal Lobe Epilepsy; A Controlled Investigation , 1969, Epilepsia.

[86]  E. Slater,et al.  The Schizophrenia-like Psychoses of Epilepsy , 1963, British Journal of Psychiatry.

[87]  Peter R Luijten,et al.  Glutamate in schizophrenia: a focused review and meta-analysis of ¹H-MRS studies. , 2013, Schizophrenia bulletin.

[88]  P. Conn,et al.  Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signaling. , 2012, Discovery medicine.

[89]  G. Macdonald,et al.  Progress in the developement of positive allosteric modulators of the metabotropic glutamate receptor 2. , 2011, Current medicinal chemistry.

[90]  W. Spooren,et al.  Metabotropic glutamate receptors: their therapeutic potential in anxiety. , 2010, Current topics in behavioral neurosciences.

[91]  M. Bialer,et al.  Key factors in the discovery and development of new antiepileptic drugs , 2010, Nature Reviews Drug Discovery.

[92]  P. Conn,et al.  Promise of mGluR2/3 activators in psychiatry , 2009, Neuropsychopharmacology.

[93]  Craig W Lindsley,et al.  Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. , 2009, Trends in pharmacological sciences.

[94]  Renate Thienel,et al.  Functional brain imaging of symptoms and cognition in schizophrenia. , 2005, Progress in brain research.

[95]  J. Kleinman,et al.  Comparative analysis of group II metabotropic glutamate receptor immunoreactivity in Brodmann's area 46 of the dorsolateral prefrontal cortex from patients with schizophrenia and normal subjects , 2002, Molecular Psychiatry.

[96]  T M Hyde,et al.  Seizures and schizophrenia. , 1997, Schizophrenia bulletin.

[97]  F. Gibbs.  Ictal and non-ictal psychiatric disorders in temporal lobe epilepsy. , 1951, The Journal of nervous and mental disease.